Clinical research - Press Releases

Date	Title	Company
11-Dec-2023	NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting	NovalGen
11-Dec-2023	New therapeutic target for rare type of childhood epilepsy	Francis Crick Institute
11-Dec-2023	ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023	ImmunOs Therapeutics
08-Dec-2023	Velocity Clinical Research expands to Poland	Velocity Clinical Research
08-Dec-2023	Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies	Sosei Heptares
06-Dec-2023	Rare disease patients are breaking down language and location barriers in a new online community	Sciensus
06-Dec-2023	Dr. Vijay Ivaturi Announced as New Chief Executive Officer at PumasAI	PumasAI
05-Dec-2023	Columbus makes offer to acquire CRO agency Endless Gain	Columbus
05-Dec-2023	Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant	Recipharm
05-Dec-2023	Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board	Thermosome GmbH
04-Dec-2023	Azalea Vision Announces First On-Eye test of ALMA, its Revolutionary	Azalea
04-Dec-2023	EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001	EBViously GmbH
30-Nov-2023	CellProthera expanding into ischemic stroke following publication of positive preclinical results with its CD34+ stem cell platform	CellProthera
30-Nov-2023	Columbus makes offer to acquire CRO agency Endless Gain	Columbus
30-Nov-2023	PHARMANOVIA STRENGTHENS MEDICAL AFFAIRS TEAM WITH KEY APPOINTMENTS TO SUPPORT GLOBAL GROWTH	Pharmanovia
30-Nov-2023	Sygnature Discovery appoints new industry leaders to their board of directors	Sygnature Discovery
29-Nov-2023	PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia	PureTech
29-Nov-2023	Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung	Oxford BioTherapeutics
29-Nov-2023	Spexis Provides Update Regarding Debt-Restructuring Moratorium	Spexis AG
29-Nov-2023	GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC	GILEAD SCIENCES